Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Myriad Genetics, Inc.    MYGN   US62855J1043

Analysis summary4-Traders Strategies 

Myriad Genetics, Inc. : Near a solid support area

02/19/2013 | 09:00am
Opinion : Bullish above USD 24.2
Target price : USD 26.1
Stop loss: USD 23.6
Advanced Medical Equipment & Technology

Myriad Genetics' share price was heavily penalized and is now in an oversold situation near to a solid support area.

Myriad Genetics is technically oversold and is near to the USD 24.2 support. This situation gives credit to a potential technical rebound. Thus, the stock could find new energy and would rise towards the next USD 26.1 resistance.

So as to make the most of a potential technical rebound of Myriad Genetics, it seems opportune to take a long position at the current price. A confirmation of this pattern would enable the security to reach the USD 27.62 resistance, with a potential gain of 13.2 %. Investors should not insist under USD 24.19 and place a stop loss order under this threshold.

Myriad Genetics, Inc. : Myriad Genetics, Inc. : Near a solid support area

© 2013

Disclaimer: is a website published by SURPERFORMANCE SAS. Surperformance or is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Financial Ratios

Size 2015e 2016e
Capitalization 2 474 M$ -
Entreprise Value (EV) 2 470 M$ 2 335 M$
Valuation 2015e 2016e
PER (Price / EPS) 26,0x 18,7x
Capitalization / Revenue 3,37x 3,09x
EV / Revenue 3,36x 2,91x
EV / EBITDA 12,2x 9,66x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,54x 3,06x
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) 24,3% 27,6%
operating Leverage (Delta EBIT / Delta Sales) -6,18x 2,64x
Net Margin (Net Profit / Revenue) 13,8% 17,7%
ROA (Net Profit / Asset) 15,8% 16,8%
ROE (Net Profit / Equities) 16,4% 17,5%
Rate of Dividend - -
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   2,74% 2,21%
Cash Flow / Sales (Taux d'autofinancement) 18,4% 20,9%
Capital Intensity (Assets / Sales) 0,88x 1,05x
Financial Leverage (Net Debt / EBITDA) -0,02x -0,58x
Income Statement Evolution
More Financials
EPS Revisions
Dynamic quotes